- Home
- ARTL vs OUSTW Comparison
ARTL vs OUSTW Comparison
Compare ARTL & OUSTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTL
- OUSTW
- Stock Information
- Founded
- ARTL 2011
- OUSTW N/A
- Country
- ARTL United States
- OUSTW United States
- Employees
- ARTL N/A
- OUSTW N/A
- Industry
- ARTL Biotechnology: Pharmaceutical Preparations
- OUSTW Industrial Machinery/Components
- Sector
- ARTL Health Care
- OUSTW Industrials
- Exchange
- ARTL Nasdaq
- OUSTW Nasdaq
- Market Cap
- ARTL 3.8M
- OUSTW 3.1M
- IPO Year
- ARTL N/A
- OUSTW N/A
- Fundamental
- Price
- ARTL $1.16
- OUSTW $0.04
- Analyst Decision
- ARTL Strong Buy
- OUSTW
- Analyst Count
- ARTL 2
- OUSTW 0
- Target Price
- ARTL $5.50
- OUSTW N/A
- AVG Volume (30 Days)
- ARTL 33.2K
- OUSTW N/A
- Earning Date
- ARTL 03-24-2025
- OUSTW N/A
- Dividend Yield
- ARTL N/A
- OUSTW N/A
- EPS Growth
- ARTL N/A
- OUSTW N/A
- EPS
- ARTL N/A
- OUSTW N/A
- Revenue
- ARTL N/A
- OUSTW N/A
- Revenue This Year
- ARTL N/A
- OUSTW N/A
- Revenue Next Year
- ARTL N/A
- OUSTW N/A
- P/E Ratio
- ARTL N/A
- OUSTW N/A
- Revenue Growth
- ARTL N/A
- OUSTW N/A
- 52 Week Low
- ARTL $0.91
- OUSTW N/A
- 52 Week High
- ARTL $1.70
- OUSTW N/A
- Technical
- Relative Strength Index (RSI)
- ARTL 43.72
- OUSTW N/A
- Support Level
- ARTL $1.15
- OUSTW N/A
- Resistance Level
- ARTL $1.24
- OUSTW N/A
- Average True Range (ATR)
- ARTL 0.10
- OUSTW 0.00
- MACD
- ARTL -0.02
- OUSTW 0.00
- Stochastic Oscillator
- ARTL 2.50
- OUSTW 0.00
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.